Synthesis and Characterization of Cefotaxime Conjugated Gold Nanoparticles and Their Use to Target Drug-Resistant CTX-M-Producing Bacterial Pathogens - PubMed (original) (raw)
. 2017 Sep;118(9):2802-2808.
doi: 10.1002/jcb.25929. Epub 2017 Apr 27.
Affiliations
- PMID: 28181300
- DOI: 10.1002/jcb.25929
Synthesis and Characterization of Cefotaxime Conjugated Gold Nanoparticles and Their Use to Target Drug-Resistant CTX-M-Producing Bacterial Pathogens
Sibhghatulla Shaikh et al. J Cell Biochem. 2017 Sep.
Abstract
Multidrug-resistance due to "β lactamases having the expanded spectrum" (ESBLs) in members of Enterobacteriaceae is a matter of continued clinical concern. CTX-M is among the most common ESBLs in Enterobacteriaceae family. In the present study, a nanoformulation of cefotaxime was prepared using gold nanoparticles to combat drug-resistance in ESBL producing strains. Here, two CTX-M-15 positive cefotaxime resistant bacterial strains (i.e., one Escherichia coli and one Klebsiella pneumoniae strain) were used for testing the efficacy of "cefotaxime loaded gold-nanoparticles." Bromelain was used for both reduction and capping in the process of synthesis of gold-nanoparticles. Thereafter, cefotaxime was conjugated onto it with the help of activator 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide. For characterization of both unconjugated and cefotaxime conjugated gold nanoparticles; UV-Visible spectroscopy, Scanning, and Transmission type Electron Microscopy methods accompanied with Dynamic Light Scattering were used. We used agar diffusion method plus microbroth-dilution method for the estimation of the antibacterial-activity and determination of minimum inhibitory concentration or MIC values, respectively. MIC values of cefotaxime loaded gold nanoparticles against E. coli and K. pneumoniae were obtained as 1.009 and 2.018 mg/L, respectively. These bacterial strains were completely resistant to cefotaxime alone. These results reinforce the utility of conjugating an old unresponsive antibiotic with gold nanoparticles to restore its efficacy against otherwise resistant bacterial pathogens. J. Cell. Biochem. 118: 2802-2808, 2017. © 2017 Wiley Periodicals, Inc.
Keywords: CEFOTAXIME; CTX-M; ESBL; GOLD NANOPARTICLES; MULTI-DRUG RESISTANCE.
© 2017 Wiley Periodicals, Inc.
Similar articles
- First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.
Lewis JS 2nd, Herrera M, Wickes B, Patterson JE, Jorgensen JH. Lewis JS 2nd, et al. Antimicrob Agents Chemother. 2007 Nov;51(11):4015-21. doi: 10.1128/AAC.00576-07. Epub 2007 Aug 27. Antimicrob Agents Chemother. 2007. PMID: 17724160 Free PMC article. - Distribution of CTX-M group I and group III β-lactamases produced by Escherichia coli and klebsiella pneumoniae in Lahore, Pakistan.
Abrar S, Vajeeha A, Ul-Ain N, Riaz S. Abrar S, et al. Microb Pathog. 2017 Feb;103:8-12. doi: 10.1016/j.micpath.2016.12.004. Epub 2016 Dec 9. Microb Pathog. 2017. PMID: 27956216 - Genetic evolution and clinical impact in extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Chong Y, Ito Y, Kamimura T. Chong Y, et al. Infect Genet Evol. 2011 Oct;11(7):1499-504. doi: 10.1016/j.meegid.2011.06.001. Epub 2011 Jun 12. Infect Genet Evol. 2011. PMID: 21689785 Review. - Antibiotic-Loaded Gold Nanoparticles: A Nano-Arsenal against ESBL Producer-Resistant Pathogens.
Rizvi SMD, Lila ASA, Moin A, Hussain T, Kamal MA, Sonbol H, Khafagy ES. Rizvi SMD, et al. Pharmaceutics. 2023 Jan 28;15(2):430. doi: 10.3390/pharmaceutics15020430. Pharmaceutics. 2023. PMID: 36839753 Free PMC article. Review.
Cited by
- In depth molecular interaction analyses of the complex of a proposed CTXM-inhibitor bound to the bacterial enzyme.
Shakil S, Rizvi SMD, Greig NH. Shakil S, et al. J Biomol Struct Dyn. 2023 Oct-Nov;41(17):8362-8372. doi: 10.1080/07391102.2022.2133009. Epub 2022 Oct 12. J Biomol Struct Dyn. 2023. PMID: 36224195 Free PMC article. - Nano-Strategies to Fight Multidrug Resistant Bacteria-"A Battle of the Titans".
Baptista PV, McCusker MP, Carvalho A, Ferreira DA, Mohan NM, Martins M, Fernandes AR. Baptista PV, et al. Front Microbiol. 2018 Jul 2;9:1441. doi: 10.3389/fmicb.2018.01441. eCollection 2018. Front Microbiol. 2018. PMID: 30013539 Free PMC article. Review. - Nano-Conversion of Ineffective Cephalosporins into Potent One against Resistant Clinical Uro-Pathogens via Gold Nanoparticles.
Rizvi SMD, Hussain T, Alshammari F, Sonbol H, Ahmad N, Faiyaz SSM, Kamal MA, Khafagy ES, Moin A, Abu Lila AS. Rizvi SMD, et al. Nanomaterials (Basel). 2023 Jan 24;13(3):475. doi: 10.3390/nano13030475. Nanomaterials (Basel). 2023. PMID: 36770436 Free PMC article. - Recent Advances in the Development of Antibiotics-Coated Gold Nanoparticles to Combat Antimicrobial Resistance.
Sarma PP, Rai A, Baruah PK. Sarma PP, et al. Antibiotics (Basel). 2024 Jan 26;13(2):124. doi: 10.3390/antibiotics13020124. Antibiotics (Basel). 2024. PMID: 38391510 Free PMC article. Review. - Metallic Nanosystems in the Development of Antimicrobial Strategies with High Antimicrobial Activity and High Biocompatibility.
Skłodowski K, Chmielewska-Deptuła SJ, Piktel E, Wolak P, Wollny T, Bucki R. Skłodowski K, et al. Int J Mol Sci. 2023 Jan 20;24(3):2104. doi: 10.3390/ijms24032104. Int J Mol Sci. 2023. PMID: 36768426 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical